Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens, Joana Barros‐Martins, Anne Cossmann, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies
Kuldeep Dhama, Firzan Nainu, Andri Frediansyah, et al.
Journal of Infection and Public Health (2022) Vol. 16, Iss. 1, pp. 4-14
Open Access | Times Cited: 199
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
Metodi V. Stankov, Markus Hoffmann, Rodrigo Gutierrez Jauregui, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 1, pp. e1-e3
Open Access | Times Cited: 46
Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2
Henning Jacobsen, Ioannis Sitaras, Maeva Katzmarzyk, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 16
COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children
Katerina Roznik, Jiashu Xue, Georgia Stavrakis, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Influence of COVID‐19 Vaccination on Treatment‐Related Adverse Events and Oncologic Outcomes of Nonmetastatic Nasopharyngeal Carcinoma
Minglong Liu, Bin Zhang, Yu‐Fei Pan, et al.
Head & Neck (2025)
Closed Access
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial
Yuzhou Gui, Xuening Li, Jingxin Li, et al.
EBioMedicine (2023) Vol. 91, pp. 104586-104586
Open Access | Times Cited: 12
Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern
Louisa Ruhl, Jenny F. Kühne, Kerstin Beushausen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
Joana Barros‐Martins, Swantje I. Hammerschmidt, Gema Morillas Ramos, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial
Christian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
Journal of Infection (2023) Vol. 87, Iss. 3, pp. 242-254
Closed Access | Times Cited: 11
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
Franz Mai, Marcel Kordt, Wendy Bergmann-Ewert, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
Matthias Becker, Anne Cossmann, Karsten Lürken, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
The Vaccine World of COVID-19: India’s Contribution
Vivek P. Chavda, Disha R. Vihol, Hetvi K. Solanki, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1943-1943
Open Access | Times Cited: 16
Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia
Jolene Yin Ling Fu, Muhammad Harith Pukhari, Maria Kahar Bador, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 844-844
Open Access | Times Cited: 7
Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine
Ivan Odak, Lennart Riemann, Inga Sandrock, et al.
EBioMedicine (2023) Vol. 99, pp. 104947-104947
Open Access | Times Cited: 7
A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022
Nicolas Guibert, Kylian Trepat, Bruno Pozzetto, et al.
Eurosurveillance (2023) Vol. 28, Iss. 15
Open Access | Times Cited: 6
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 9, pp. 1253-1262
Open Access | Times Cited: 6
Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
Ivan Odak, Christian Schultze-Florey, Swantje I. Hammerschmidt, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial
Yuzhou Gui, Ye Cao, Jiajin He, et al.
Life Metabolism (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 5
Label-Free Mapping of Multivalent Binding Pathways with Ligand–Receptor-Anchored Nanopores
Hui Ma, Yongyong Wang, Y F Li, et al.
Journal of the American Chemical Society (2024)
Closed Access | Times Cited: 1
Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Larissa Henze, Julian Braun, Lil Meyer-Arndt, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Complementarity determining regions in SARS-CoV-2 hybrid immunity
Glynis Frans, Doreen Dillaerts, Tom Dehaemers, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
Niko Kohmer, Shivana Stein, Barbara Schenk, et al.
International Journal of Infectious Diseases (2022) Vol. 128, pp. 166-175
Open Access | Times Cited: 7
mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals
Roberto Lozano‐Rodríguez, José Avendaño‐Ortiz, Verónica Terrón, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
Metodi V. Stankov, Markus Hoffmann, Rodrigo Gutierrez Jauregui, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top